For agencies
What we do and do not do
The scope boundary in plain language, so that nobody discovers it in month four.
What IntellaRx does
- Supplies clinical context — diagnosis, treatment plan, prior therapy, comorbidity and metabolic profile — to the clinicians and pharmacists making decisions.
- Confirms that a controlled medication reached the person it was prescribed for, and that a specimen came from the person the result will be attached to.
- Delivers medication in partnership with licensed pharmacies to patients who cannot reliably collect it themselves.
- Screens for behavioral health comorbidity with validated instruments and returns critical findings to clinicians.
- Assesses social circumstances with the patient, and refers where there is a need.
- Detects changes in a local drug supply at population level and produces warnings.
- Maintains an aggregate, current picture of overdose events for an agency’s jurisdiction.
- Reports program outcomes, including bad ones.
What IntellaRx does not do
- It does not prescribe, dispense, diagnose or treat. It is not a clinic and not a pharmacy.
- It does not determine any agency’s regulatory obligations. Whether HIPAA, 42 CFR Part 2, state confidentiality law, corrections rules or public records law apply to a given arrangement is a determination for that agency and its counsel. We describe what the program does in enough detail for them to make it. We do not make it for them, and we would be wrong to.
- It does not build enforcement cases. No component is designed to identify individuals for prosecution, and we decline deployments that would use them that way.
- It does not score patients by suspicion.
- It does not monitor individuals’ social media. See drug-supply signal analysis, which operates on aggregate public material about a drug market.
- It does not report individual behavioral health, social or monitoring data to an agency. Agencies receive aggregate outcomes.
- It does not make treatment conditional on participation. Declining any component — biometric enrollment, a site visit, monitoring — does not remove anyone from care.
- It does not give legal or medical advice through this site or otherwise.
On the 42 CFR Part 2 question specifically
Agencies sometimes assume that if one confidentiality regime does not apply to them, none does. That is not a safe assumption, and it is worth naming because substance use disorder information is governed by a separate federal regime — 42 U.S.C. § 290dd-2 and 42 C.F.R. Part 2 — with its own scope and its own requirements, which in several respects are stricter than HIPAA’s.
We are not telling you whether it applies to you. We are telling you not to conclude that it does not because something else does not. That is a question for your counsel, and it is one worth asking early rather than after a data flow is built.
On pricing
IntellaRx does not publish prices. Scope varies enormously with population size, which components are deployed, and what systems an agency already has, so a published figure would be misleading rather than helpful. Cost is discussed in scoping, in writing, against a defined scope.
Questions this raises
Will you tell us whether HIPAA applies to our program?
No. That is a legal determination about your organization, it varies with the agency, the population and the arrangement, and it is not ours to make. We will describe exactly what data the program touches, where it comes from, who can see it and how long it is held, so that your counsel can make the determination. Be cautious of any vendor who answers this question for you. See questions worth asking a vendor.
Can the program be used to support enforcement activity?
No, and we decline deployments structured that way. Every clinical component depends on patients answering honestly, and a program believed to feed enforcement stops receiving honest answers almost immediately. That is not only an ethical objection; it is why such a deployment would not work. See why trust is load-bearing.